CureVac (NASDAQ:CVAC) Stock Price Up 7.5% – Time to Buy?

Shares of CureVac (NASDAQ:CVAC) were up 7.5% on Friday . The stock traded as high as $3.05 and last traded at $3.08. Approximately 220,809 shares traded hands during trading, a decline of 73% from the average daily volume of 809,843 shares. The stock had previously closed at $2.86.

Analyst Ratings Changes

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a research report on Friday, February 14th.

CureVac Price Performance

The firm has a market cap of $699.63 million, a price-to-earnings ratio of 5.66 and a beta of 2.48. The company’s fifty day moving average is $3.13 and its 200 day moving average is $3.16. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

Hedge Funds Weigh In On CureVac

A number of large investors have recently modified their holdings of CVAC. Integrated Wealth Concepts LLC bought a new stake in CureVac during the third quarter worth about $35,000. Two Sigma Advisers LP bought a new stake in shares of CureVac during the 4th quarter worth approximately $48,000. Jump Financial LLC bought a new stake in shares of CureVac during the 4th quarter worth approximately $55,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of CureVac in the 4th quarter valued at approximately $66,000. Finally, Barclays PLC bought a new position in shares of CureVac in the third quarter valued at $67,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.